Department of Large Animal Clinics, Federal University of Santa Maria, Veterinary Teaching Hospital, Santa Maria, Rio Grande do Sul, Brazil.
Department of Large Animal Clinics, Equine Sports Medicine and Surgery, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil.
J Equine Vet Sci. 2022 Mar;110:103865. doi: 10.1016/j.jevs.2022.103865. Epub 2022 Jan 10.
Botulinum toxin type A (BoNT-A) is a promising alternative for patients suffering from chronic joint pain. The aim of this study was to investigate whether a single injection of BoNT-A would produce adverse effects on clinical parameters and synovial parameters as well as lameness. One randomly selected radiocarpal joint was treated with 50 U of BoNT-A in eight horses, and the contralateral joint received saline solution. All horses received injections at day 0 and were re-evaluated twice daily for 7 days for heart rate (HR), respiratory rate (RR), rectal temperature (RT), mucous membrane color, capillary refill time, intestinal motility, appetite, water intake, defecation, urination, and attitude. At these same time points, joint pain and circumference were assessed. Objective lameness evaluations were performed once daily for 7 days and synovial fluid samples were collected at baseline, post-injection hour (PIH) 24 and PIH 168 and evaluated for synovial fluid parameters. HR and RT remained clinically unaltered, despite oscillations over time (P = .001). The remaining clinical parameters were unaltered by treatment or time (P > .05). Joint pain was not elicited by flexion and palpation in both limbs as well as carpal circumference was not altered (P = .88). Lameness was observed only on saline limbs. Cellular parameters evaluated in synovial fluid samples from both carpi had significantly increased from baseline to PIH 24, decreasing at PIH 168 (P < .05). It was concluded that the injection of 50 U BoNT-A is suggested to be a safe therapy for intra-articular use in horses and must be verified by further investigation.
肉毒毒素 A 型（BoNT-A）是治疗慢性关节疼痛患者的一种很有前途的选择。本研究旨在探讨单次注射 BoNT-A 是否会对临床参数、滑膜参数以及跛行产生不良影响。在 8 匹马中，随机选择一个腕关节接受 50 U 的 BoNT-A 治疗，对侧关节接受生理盐水治疗。所有马均在第 0 天接受注射，并在接下来的 7 天内每天进行两次评估，评估指标包括心率（HR）、呼吸频率（RR）、直肠温度（RT）、黏膜颜色、毛细血管再充盈时间、肠道蠕动、食欲、饮水量、排便、排尿和姿势。同时，评估关节疼痛和周长。7 天内每天进行一次客观跛行评估，并在基线、注射后 24 小时（PIH 24）和 PIH 168 时采集滑液样本，评估滑液参数。尽管存在时间波动（P = 0.001），但 HR 和 RT 仍保持临床不变。治疗或时间均未改变其余临床参数（P > 0.05）。双侧肢体的关节弯曲和触诊均未引起疼痛，且腕关节周长未改变（P = 0.88）。仅在生理盐水治疗的肢体上观察到跛行。从基线到 PIH 24，两个腕关节滑液样本的细胞参数均显著增加，在 PIH 168 时下降（P < 0.05）。综上所述，注射 50 U 的 BoNT-A 被认为是一种安全的关节内治疗方法，还需要进一步研究验证。
